Mark Clemons

4.4k total citations · 2 hit papers
29 papers, 3.4k citations indexed

About

Mark Clemons is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Mark Clemons has authored 29 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Genetics. Recurrent topics in Mark Clemons's work include Cancer Treatment and Pharmacology (8 papers), Estrogen and related hormone effects (7 papers) and Breast Cancer Treatment Studies (7 papers). Mark Clemons is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Estrogen and related hormone effects (7 papers) and Breast Cancer Treatment Studies (7 papers). Mark Clemons collaborates with scholars based in Canada, New Zealand and United Kingdom. Mark Clemons's co-authors include Paul E. Goss, Karen A. Gelmon, Amit M. Oza, Helen Mackay, Euan Macpherson, Rinat Yerushalmi, Katia Tonkin, C. Blake Gilks, Marc Tischkowitz and James Carmichael and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Mark Clemons

29 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

2011 850 citations Karen A. Gelmon, Marc Tischkowitz et al. The Lancet Oncology profile →
Estrogen and the Risk of Breast Cancer

2001 830 citations Mark Clemons, Paul E. Goss profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Clemons Canada	20	2.2k	1.1k	825	729	628	29	3.4k
Sacha J. Howell United Kingdom	35	2.1k 1.0×	1.7k 1.5×	886 1.1×	703 1.0×	1.0k 1.6×	146	4.4k
Gordan Srkalović United States	31	1.8k 0.8×	1.6k 1.4×	261 0.3×	389 0.5×	556 0.9×	91	3.6k
Banu Arun United States	23	1.8k 0.8×	1.5k 1.4×	800 1.0×	466 0.6×	897 1.4×	58	3.3k
Darcy Spicer United States	29	2.0k 1.0×	880 0.8×	846 1.0×	675 0.9×	813 1.3×	91	3.8k
Nicoletta Biglia Italy	41	1.6k 0.8×	1.4k 1.2×	1.3k 1.5×	455 0.6×	1.3k 2.1×	195	5.0k
Larissa A. Korde United States	27	1.7k 0.8×	764 0.7×	810 1.0×	767 1.1×	1.0k 1.7×	81	3.7k
Susan Minton United States	22	1.4k 0.6×	1.4k 1.3×	348 0.4×	351 0.5×	563 0.9×	41	2.9k
Paola Ferrari Italy	28	837 0.4×	957 0.9×	380 0.5×	340 0.5×	496 0.8×	103	2.6k
Laura P. Stabile United States	34	1.8k 0.8×	1.4k 1.3×	722 0.9×	1.3k 1.8×	504 0.8×	88	3.4k
Kimberly K. Leslie United States	42	1.3k 0.6×	1.9k 1.8×	1.2k 1.4×	515 0.7×	902 1.4×	186	5.6k

Countries citing papers authored by Mark Clemons

Since Specialization

Citations

This map shows the geographic impact of Mark Clemons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Clemons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Clemons more than expected).

Fields of papers citing papers by Mark Clemons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Clemons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Clemons. The network helps show where Mark Clemons may publish in the future.

Co-authorship network of co-authors of Mark Clemons

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Clemons. A scholar is included among the top collaborators of Mark Clemons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Clemons. Mark Clemons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Addison, Christina, et al.. (2013). Incidence and consequences of bone metastases in lung cancer patients. Journal of bone oncology. 2(1). 22–29. 72 indexed citations

Freedman, Orit, Eitan Amir, Camilla Zimmermann, & Mark Clemons. (2011). Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Supportive Care in Cancer. 19(3). 315–322. 6 indexed citations

Bouganim, Nathaniel, George Dranitsaris, Eitan Amir, & Mark Clemons. (2011). Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Supportive Care in Cancer. 19(11). 1687–1696. 26 indexed citations

Gelmon, Karen A., Marc Tischkowitz, Helen Mackay, et al.. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncology. 12(9). 852–861. 850 indexed citations breakdown →

Harris, Kristin, Edward Chow, Liying Zhang, et al.. (2009). Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastases. European Journal of Cancer. 45(14). 2510–2518. 44 indexed citations

Parissenti, Amadeo M., Judy‐Anne W. Chapman, Harriette J. Kahn, et al.. (2009). Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. 119(2). 347–356. 13 indexed citations

Enright, Katherine, Rebecca Dent, George Dranitsaris, et al.. (2009). Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. Clinical Breast Cancer. 9(1). 29–33. 354 indexed citations

Amir, Eitan, Christine Simmons, Orit Freedman, et al.. (2009). A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D₃ in breast cancer patients with bone metastases. Cancer. 116(2). 284–291. 55 indexed citations

Simmons, Christine, et al.. (2008). Pharmacotherapy of bone metastases in breast cancer patients. Expert Opinion on Pharmacotherapy. 9(6). 937–945. 7 indexed citations

10.

Goodwin, Pamela J., Kathleen I. Pritchard, Marguerite Ennis, et al.. (2008). Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. Clinical Breast Cancer. 8(6). 501–505. 181 indexed citations

11.

Whyne, Cari, Michael Hardisty, Florence T.H. Wu, et al.. (2007). Quantitative characterization of metastatic disease in the spine. Part II. Histogram‐based analyses. Medical Physics. 34(8). 3279–3285. 23 indexed citations

12.

Leighl, Natasha B., Susan Dent, Mark Clemons, et al.. (2007). A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 108(1). 87–92. 60 indexed citations

13.

Booth, Christopher M., George Dranitsaris, M. Corona Gainford, et al.. (2007). External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. BMC Cancer. 7(1). 110–110. 28 indexed citations

14.

Fan, Helen G. Mar, Mark Clemons, Wei Xu, et al.. (2007). A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Supportive Care in Cancer. 16(6). 577–583. 150 indexed citations

15.

Verma, Sunil, Nan Soon Wong, Maureen Trudeau, et al.. (2007). Survival Differences Observed in Metastatic Breast Cancer Patients Treated With Capecitabine When Compared With Vinorelbine After Pretreatment With Anthracycline and Taxane. American Journal of Clinical Oncology. 30(3). 297–302. 17 indexed citations

16.

Clemons, Mark & Christine Simmons. (2006). Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Research and Treatment. 104(2). 115–120. 27 indexed citations

17.

Chia, Stephen, et al.. (2006). Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology. 24(18). 2773–2778. 104 indexed citations

18.

Clemons, Mark, et al.. (2002). Management of the menopause in cancer survivors. Cancer Treatment Reviews. 28(6). 321–333. 7 indexed citations

19.

Clamp, Andrew R., Sarah Danson, & Mark Clemons. (2002). Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. The Lancet Oncology. 3(10). 611–619. 34 indexed citations

20.

Goss, Paul E., Kathrin Strasser, Mark Clemons, et al.. (2000). Liarozole Fumarate (R85246): In the Treatment of ER Negative, Tamoxifen Refractory or Chemotherapy Resistant Postmenopausal Metastatic Breast Cancer. Breast Cancer Research and Treatment. 64(2). 177–188. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact